Rubioncolin C exhibits potential in antimicrobial applications, particularly against Gram-positive bacteria. Studies suggest it may interfere with bacterial cell wall synthesis, making it a candidate for development in antibiotic therapies. It has also shown moderate antifungal activity in preliminary in vitro tests. Additionally, Rubioncolin C demonstrates cytotoxic effects on certain tumor cell lines, indicating possible utility in anticancer research. Its natural origin and unique structure support further investigation for pharmaceutical use, especially in targeting drug-resistant pathogens.